Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEXATE vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MEXATE is an antimetabolite that inhibits dihydrofolate reductase (DHFR), reducing tetrahydrofolate synthesis and interfering with DNA, RNA, and protein synthesis. It also inhibits thymidylate synthetase and has immunomodulatory and anti-inflammatory effects.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Rheumatoid arthritis (moderate to severe active disease in adults),Polyarticular juvenile idiopathic arthritis,Psoriasis (severe, recalcitrant, disabling),Neoplastic diseases: gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole; acute lymphocytic leukemia (ALL); meningeal leukemia; Burkitt lymphoma; advanced non-Hodgkin lymphomas; mycosis fungoides; advanced head and neck cancer; osteosarcoma (adjunctive treatment),Off-label: ectopic pregnancy, inflammatory bowel disease, graft-versus-host disease, sarcoidosis, systemic lupus erythematosus, vasculitis
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
10-25 mg/m2 orally or intramuscularly once weekly for rheumatoid arthritis; 50 mg/m2 intravenously once weekly for psoriasis; 30-40 mg/m2 intravenously weekly for certain cancers (dose varies by protocol).
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life is 3-10 hours for low-dose therapy (≤30 mg/m²). For high-dose therapy (>100 mg/m²), terminal half-life extends to 8-15 hours due to saturable elimination. A third, prolonged terminal phase (8-72 hours) is observed in some patients due to enterohepatic recirculation.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Methotrexate is primarily metabolized by hepatic aldehyde oxidase to 7-hydroxymethotrexate. It undergoes polyglutamation intracellularly. Less than 10% is metabolized by cytochrome P450 enzymes. Excretion is primarily renal via glomerular filtration and active tubular secretion.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Renal excretion of unchanged drug is the primary route of elimination, accounting for 80-90% of the dose. Biliary/fecal excretion is minor (<10%).
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
50-60% bound, primarily to albumin.
Approximately 85-90% bound to serum albumin.
0.4-0.8 L/kg (total body water). Vd increases with dose, indicating tissue distribution.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral: 30-70% (dose-dependent, saturable absorption). Intramuscular: 80-100%. Subcutaneous: approximately 100%.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: 75% of normal dose; Child-Pugh B: 50% of normal dose; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
For leukemia: 20-40 mg/m2 orally or intravenously once weekly; for juvenile idiopathic arthritis: 10-15 mg/m2 orally once weekly (max 25 mg/week).
Not established; safety and efficacy not determined in pediatric patients.
Start at lowest effective dose (e.g., 5-7.5 mg/week) with close monitoring of renal function, hepatic function, and hematologic parameters due to increased toxicity risk.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
Boxed Warning: Methotrexate (MEXATE) can cause severe or fatal toxicities including bone marrow suppression, hepatic fibrosis/cirrhosis, pulmonary fibrosis, renal failure, and ulcerative stomatitis. Fatalities have been reported with inadvertent daily dosing instead of weekly. For rheumatoid arthritis and psoriasis, use only in patients with severe disease. Monitor for toxicity closely. Advise patients about risks of fatal toxicity.
None.
Severe hematologic toxicity (bone marrow suppression, pancytopenia), hepatotoxicity (fibrosis, cirrhosis, acute hepatitis), pulmonary toxicity (pneumonitis, fibrosis), renal toxicity, gastrointestinal toxicity (stomatitis, ulceration), neurotoxicity (leukoencephalopathy), opportunistic infections, tumor lysis syndrome, photosensitivity, and dermatologic reactions. Avoid concomitant NSAIDs, salicylates, and nephrotoxic drugs. Monitor CBC, LFTs, creatinine, and chest imaging. Use caution in elderly, debilitated, or patients with renal impairment, ascites, or pleural effusions.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to methotrexate, alcohol abuse, pre-existing liver disease (including hepatitis), renal impairment (creatinine clearance < 60 m L/min), pre-existing bone marrow suppression, immunodeficiency, active infections (e.g., tuberculosis), pregnancy, breastfeeding, lactation.
Hypersensitivity to AURLUMYN or any of its components.
Avoid alcohol due to increased hepatotoxicity risk. No specific food restrictions; however, maintain adequate hydration. Folate-rich foods do not interfere but supplemental folic acid may be prescribed to reduce side effects.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Category X. 1st trimester: High risk of CNS, craniofacial, and skeletal malformations. 2nd and 3rd trimesters: Fetal growth restriction, oligohydramnios, and neonatal pancytopenia.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Contraindicated. Methotrexate is excreted in human milk; M/P ratio approximately 0.08. Potential for severe neonatal toxicity.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Not applicable; contraindicated in pregnancy. If inadvertent exposure, discontinue and refer for fetal assessment.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Mexate (methotrexate) is a folate analog antimetabolite used in high doses for malignancy and low doses for autoimmune diseases. Reserve leucovorin rescue for high-dose protocols to prevent severe myelosuppression. Monitor renal function and methotrexate levels; adjust hydration and alkalinization to prevent precipitation in renal tubules. Avoid concurrent NSAIDs and proton pump inhibitors which reduce methotrexate clearance. Screen for pregnancy before initiation. Administer weekly in low-dose regimens for rheumatoid arthritis to avoid acute toxicity.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Take exactly as prescribed—do not increase dose or frequency. Overdose can be fatal.,Avoid alcohol completely while on this medication.,Report any signs of infection, unusual bleeding, bruising, or mouth sores immediately.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not take NSAIDs or aspirin without consulting your doctor.,Stay well hydrated; drink plenty of fluids unless otherwise instructed.,Avoid live vaccines during treatment.,Keep all follow-up appointments for blood tests and monitoring.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEXATE vs AURLUMYN, answered by our medical review team.
MEXATE is a Antineoplastic Agent that works by MEXATE is an antimetabolite that inhibits dihydrofolate reductase (DHFR), reducing tetrahydrofolate synthesis and interfering with DNA, RNA, and protein synthesis. It also inhibits thymidylate synthetase and has immunomodulatory and anti-inflammatory effects.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEXATE and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEXATE is: 10-25 mg/m2 orally or intramuscularly once weekly for rheumatoid arthritis; 50 mg/m2 intravenously once weekly for psoriasis; 30-40 mg/m2 intravenously weekly for certain cancers (dose varies by protocol).. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEXATE and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEXATE is classified as Category C. Category X. 1st trimester: High risk of CNS, craniofacial, and skeletal malformations. 2nd and 3rd trimesters: Fetal growth restriction, oligohydramnios, and neonatal pancytopenia.. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.